Neuroprotection by selegiline and other MAO inhibitors

Journal of Neural Transmission, Supplement

Volumn , Issue 52, 1998, Pages 99-107

  Stern, G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); MONOAMINE OXIDASE INHIBITOR; SELEGILINE; ANTIPARKINSON AGENT; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; ENZYME ACTIVITY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RAT; ANIMAL; BLOOD PRESSURE; BODY POSTURE; CLINICAL TRIAL; DRUG EFFECT; HUMAN; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; ANTIPARKINSON AGENTS; BLOOD PRESSURE; CLINICAL TRIALS; HUMANS; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; POSTURE; PROSPECTIVE STUDIES; SELEGILINE;

EID: 0031596685     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6499-0_12     Document Type: Article

References (24)

1. Beringer K (1928) Über ein neues, auf das extrapyramidal-motorische System wirkendes Alkaloid (Banisterin). Nervenarzt 1: 265-275
2. Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975) The potentiation of the anti-akinetic effect after 1-dopa treatment by an inhibitor of MAO-B, Deprenyl. J Neural Transm 36: 303-326
3. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Harts V, Marton J (1985) Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a long-term study. J Neural Transm 64: 113-127
4. Blaschko H, Richter D, Schlossmann H (1937) The inactivation of adrenaline. J Physiol (Lond) 90: 1-15
5. Blaschko H, Richter D, Schlossmann H (1937) The oxidation of adrenaline and other amines. Biochem J 31: 2187-2196
6. Elsworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Phuapradit P, Shaw KM, Stern GM, Kumar P (1978) Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the "cheese effect". Psychopharmacology 57: 33-38
7. Halpern L (1930) Ueber die Harminwirkung im Selbstversuch. Dtsch Med Wochenschr 56: 1252-1254
8. Hare MLC (1928) Tyramine oxidase. 1. A new enzyme system in the liver. Biochem J 22: 968-979
9. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467-469
10. Knoll J (1978) The possible mechanisms of action of (-)-deprenyl in Parkinson's disease. J Neural Transm 43: 177-198
11. Knoll J, Ecsery Z, Kelemen K, Nievel JG, Knoll B (1965) Phenylpropylmethylpropinylamine (E-250): a new spectrum psychic energizer. Arch Int Pharmacodyn 155: 154-164
12. Lees AJ, Shaw KM, Kohout L, Stern GM, Elsworth JD, Sandler M, Youdim MBH (1977) Deprenyl in Parkinson's disease. Lancet ii: 791-795
13. Lewin L (1928) Untersuchungen uber Banisterin caapi Spr. Arch Exp Pathol Pharmakol 129: 133-149
14. Lewin L, Schuster P (1929) Ergebnisse von Banisterinversuchen an Kranken. Dtsch Med Wochenschr 55: 149
15. Mann J, Gershon S (1980) L-deprenyl, a selective monoamine oxidase inhibitor in endogenous depression. Life Sci 26: 877-882
16. The Parkinson's Disease Research Group of the UK (1993) Comparison of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 307: 469-472
17. The Parkinson's Disease Research Group of the UK (1995) Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 311: 1602-1607
18. The Parkinson's Disease Research Group of the UK (1996) BMJ 312: 704-705 (letter)
19. The Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321: 1364-1371
20. The Parkinson Study Group (1996) Impact of Deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 39: 29-36
21. The Parkinson Study Group (1996) Impact of Deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects requiring levodopa. Ann Neurol 39: 37-45
22. Reynolds GP, Elsworth JD, Blau K, Sandler M, Lees AJ, Stern GM (1978) Deprenyl is metabolised to methamphetamine and amphetamine in man. Br J Clin Pharmacol 6: 542-544
23. Spruce R (1908) Notes of a Botanist on the Amazon and Ande, vol 11. Macmillan, London
24. Udenfriend S, Witkop B, Redfield BG, Wiessbach H (1958) Studies with reversible inhibitors of monoamine oxidase: harmaline and related compounds. Biochem Pharmacol 1: 160-165